Structure Therapeutics Inc. Investing Cash Flow
Structure Therapeutics Inc. (GPCR) reported Investing Cash Flow of -$422.45 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Investing Activities
us-gaap:NetCashProvidedByUsedInInvestingActivities · last filed 2026-08-06
- Structure Therapeutics Inc. net cash provided by (used in) investing activities for the quarter ending 2026-06-30 was $74.50M, a 52.22% increase year-over-year.
- Structure Therapeutics Inc. net cash provided by (used in) investing activities for the quarter ending 2026-03-31 was -$496.95M, a 1560.19% decline year-over-year.
- Structure Therapeutics Inc. net cash provided by (used in) investing activities for the quarter ending 2025-12-31 was $56.14M, a 68.93% increase year-over-year.
- Structure Therapeutics Inc. net cash provided by (used in) investing activities for the quarter ending 2025-09-30 was -$49.32M.
- Structure Therapeutics Inc. net cash provided by (used in) investing activities for fiscal 2025 was $89.80M.
- Structure Therapeutics Inc. net cash provided by (used in) investing activities for fiscal 2024 was -$358.91M.
- Structure Therapeutics Inc. net cash provided by (used in) investing activities for fiscal 2023 was -$268.34M.
- Structure Therapeutics Inc. net cash provided by (used in) investing activities for fiscal 2022 was -$62.11M.
| Period end | Net Cash Provided by (Used in) Investing Activities 3 month | Net Cash Provided by (Used in) Investing Activities 6 month | Net Cash Provided by (Used in) Investing Activities 9 month | Net Cash Provided by (Used in) Investing Activities 12 month |
|---|---|---|---|---|
| 2026-06-30 | $74.50M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | -$422.45M 10-Q · filed 2026-08-06 | -$366.31M derived: sum of 3 quarters · filed 2026-08-06 | -$415.63M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | -$496.95M 10-Q · filed 2026-05-07 | -$440.81M derived: sum of 2 quarters · filed 2026-05-07 | -$490.13M derived: sum of 3 quarters · filed 2026-05-07 | -$441.18M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $56.14M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $6.82M derived: sum of 2 quarters · filed 2026-02-26 | $55.76M derived: sum of 3 quarters · filed 2026-08-06 | $89.80M 10-K · filed 2026-02-26 |
| 2025-09-30 | -$49.32M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | -$377.00K derived: sum of 2 quarters · filed 2026-08-06 | $33.66M 10-Q · filed 2025-11-06 | $66.89M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $48.94M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $82.97M 10-Q · filed 2026-08-06 | $116.21M derived: sum of 3 quarters · filed 2026-08-06 | -$72.84M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $34.03M 10-Q · filed 2026-05-07 | $67.27M derived: sum of 2 quarters · filed 2026-05-07 | -$121.78M derived: sum of 3 quarters · filed 2026-05-07 | -$326.29M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $33.23M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | -$155.81M derived: sum of 2 quarters · filed 2026-02-26 | -$360.33M derived: sum of 3 quarters · filed 2026-02-26 | -$358.91M 10-K · filed 2026-02-26 |
| 2024-09-30 | -$189.04M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | -$393.56M derived: sum of 2 quarters · filed 2025-11-06 | -$392.14M 10-Q · filed 2025-11-06 | -$572.88M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-06-30 | -$204.51M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-06 | -$203.10M 10-Q · filed 2025-08-06 | -$383.84M derived: sum of 3 quarters · filed 2026-02-26 | -$353.71M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-03-31 | $1.42M 10-Q · filed 2025-05-08 | -$179.33M derived: sum of 2 quarters · filed 2026-02-26 | -$149.20M derived: sum of 3 quarters · filed 2026-02-26 | -$217.91M derived: sum of 4 quarters · filed 2026-02-26 |
| 2023-12-31 | -$180.74M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | -$150.62M derived: sum of 2 quarters · filed 2026-02-26 | -$219.33M derived: sum of 3 quarters · filed 2026-02-26 | -$268.34M 10-K · filed 2026-02-26 |
| 2023-09-30 | $30.13M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-13 | -$38.58M derived: sum of 2 quarters · filed 2024-11-13 | -$87.60M 10-Q · filed 2024-11-13 | -$77.26M derived: sum of 4 quarters · filed 2024-11-13 |
| 2023-06-30 | -$68.71M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | -$117.73M 10-Q · filed 2024-08-08 | -$107.39M derived: sum of 3 quarters · filed 2024-08-08 | -$124.04M derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-03-31 | -$49.02M 10-Q · filed 2024-05-09 | -$38.67M derived: sum of 2 quarters · filed 2024-05-09 | -$55.33M derived: sum of 3 quarters · filed 2024-05-09 | -$71.41M derived: sum of 4 quarters · filed 2024-05-09 |
| 2022-12-31 | $10.34M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-08 | -$6.32M derived: sum of 2 quarters · filed 2024-03-08 | -$22.39M derived: sum of 3 quarters · filed 2024-03-08 | -$62.11M 10-K · filed 2024-03-08 |
| 2022-09-30 | -$16.66M derived: 10-Q 9 month − 10-Q/A 6 month · filed 2023-11-17 | -$32.73M derived: sum of 2 quarters · filed 2023-11-17 | -$72.45M 10-Q · filed 2023-11-17 | |
| 2022-06-30 | -$16.07M derived: 10-Q/A 6 month − 10-Q 3 month · filed 2023-11-17 | -$55.79M 10-Q/A · filed 2023-11-17 | ||
| 2022-03-31 | -$39.72M 10-Q · filed 2023-05-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 | |
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |